Avalyn Pharma (NASDAQ:AVLN) Posts Earnings Results, Misses Estimates By $5.45 EPS

Avalyn Pharma (NASDAQ:AVLN) released its quarterly earnings data on Wednesday. The company reported ($21.83) EPS for the quarter, missing the consensus estimate of ($16.38) by ($5.45), Zacks reports.

Avalyn Pharma Price Performance

Avalyn Pharma stock opened at $26.40 on Thursday. Avalyn Pharma has a 52 week low of $24.15 and a 52 week high of $32.22.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on AVLN shares. Jefferies Financial Group started coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They issued a “buy” rating and a $52.00 price objective on the stock. Evercore started coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price objective on the stock. Zacks Research upgraded shares of Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Morgan Stanley started coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 price objective on the stock. Finally, Guggenheim started coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They issued a “buy” rating and a $80.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $59.00.

Insider Transactions at Avalyn Pharma

In related news, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was purchased at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the transaction, the insider owned 2,186,562 shares in the company, valued at $39,358,116. This trade represents a 34.06% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jill Carroll acquired 277,778 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were bought at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the transaction, the director owned 2,186,562 shares in the company, valued at $39,358,116. This represents a 14.55% increase in their position. The disclosure for this purchase is available in the SEC filing.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.